Skip to content
Disclosery

RP Management, LLC

Follow

13F filer, CIK 1507673, New York, NY

RP Management, LLC reported $138,841,811 across 4 holdings for the quarter ended 2025-03-31, in a 13F-HR filed 2025-05-02.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001507673-25-000009

Period
2025-03-31
Reported value
$139M
Holdings
4
Top 10 weight
100%
New
0
Sold out
0

Holdings, Q1 2025

Share positions as resolved from 13F-HR 0001507673-25-000009, largest first. % of portfolio is the value over $138,841,811, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
BHVNBIOHAVEN LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: 2,936,507 shares; 2023Q4: 2,936,507 shares; 2024Q1: 2,936,507 shares; 2024Q2: 2,936,507 shares; 2024Q3: 2,936,507 shares; 2024Q4: 2,936,507 shares; 2025Q1: 2,936,507 shares 2,936,507$70.6M50.84%0Timeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 980,392 shares; 2024Q3: 980,392 shares; 2024Q4: 980,392 shares; 2025Q1: 980,392 shares 980,392$39.4M28.38%0Timeline
BCRXBIOCRYST PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: 3,846,154 shares; 2023Q4: 3,846,154 shares; 2024Q1: 3,846,154 shares; 2024Q2: 3,846,154 shares; 2024Q3: 3,846,154 shares; 2024Q4: 3,846,154 shares; 2025Q1: 3,846,154 shares 3,846,154$28.8M20.78%0Timeline
VIRACTA THERAPEUTICS INCVIRACTA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: 3,700 shares; 2023Q4: 3,700 shares; 2024Q1: 3,700 shares; 2024Q2: 3,700 shares; 2024Q3: 3,700 shares; 2024Q4: 3,700 shares; 2025Q1: 3,700 shares 3,700$74<0.01%0

How Q1 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001507673-25-000009 base2025-05-02acceptance time not in the bulk data set